TISIDB

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Lipid-anchor; Cytoplasmic side. Early endosome membrane Lipid-anchor. Note=Enriched in endosomes that are in close proximity to clathrin-enriched regions at the cell surface.
Domain	PF01363 FYVE zinc finger PF11464 Rabenosyn Rab binding domain
Function	Rab4/Rab5 effector protein acting in early endocytic membrane fusion and membrane trafficking of recycling endosomes. Required for endosome fusion either homotypically or with clathrin coated vesicles. Plays a role in the lysosomal trafficking of CTSD/cathepsin D from the Golgi to lysosomes. Also promotes the recycling of transferrin directly from early endosomes to the plasma membrane. Binds phospholipid vesicles containing phosphatidylinositol 3-phosphate (PtdInsP3) (PubMed:11062261, PubMed:11788822, PubMed:15020713). Plays a role in the recycling of transferrin receptor to the plasma membrane (PubMed:22308388).

> Gene Ontology [ TOP ]
Biological Process	GO:0000011 vacuole inheritance GO:0006892 post-Golgi vesicle-mediated transport GO:0006895 Golgi to endosome transport GO:0006896 Golgi to vacuole transport GO:0006906 vesicle fusion GO:0007030 Golgi organization GO:0007033 vacuole organization GO:0007034 vacuolar transport GO:0007041 lysosomal transport GO:0007596 blood coagulation GO:0007599 hemostasis GO:0016050 vesicle organization GO:0016197 endosomal transport GO:0016482 cytosolic transport GO:0034058 endosomal vesicle fusion GO:0034498 early endosome to Golgi transport GO:0042147 retrograde transport, endosome to Golgi GO:0044801 single-organism membrane fusion GO:0048193 Golgi vesicle transport GO:0048284 organelle fusion GO:0048308 organelle inheritance GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0061025 membrane fusion GO:0090160 Golgi to lysosome transport GO:0090174 organelle membrane fusion GO:1903358 regulation of Golgi organization
Molecular Function	GO:0017016 Ras GTPase binding GO:0017137 Rab GTPase binding GO:0031267 small GTPase binding GO:0051020 GTPase binding
Cellular Component	GO:0005769 early endosome GO:0010008 endosome membrane GO:0010009 cytoplasmic side of endosome membrane GO:0031901 early endosome membrane GO:0044440 endosomal part GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis
Reactome	R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade R-HSA-168898: Toll-Like Receptors Cascades

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RBSN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RBSN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RBSN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	1
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	1
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	1
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.076	0.812
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.23	0.877
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.089	0.957
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.283	0.716
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.464	0.651
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.201	0.00114

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RBSN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	14.8	0.00448
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	14.8	0.00826
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RBSN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RBSN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RBSN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RBSN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RBSN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RBSN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RBSN
Name	rabenosyn, RAB effector
Aliases	Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location	3p25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RBSN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse RBSN